Sign in
4

Changes in Ownership

Sionna Therapeutics, Inc. Filed Acc 0001704336-25-000004

President & CEO sold 25,000 shares at an average $29.11 ($727,798)

  • President & CEO acquired 25,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Cloonan Michael President & CEO 2025-09-26 Option exercise 10b5-1 +17,207 $6.11 $105,135 564,550 D: show line 1 in the form
Cloonan Michael President & CEO 2025-09-26 Sale 10b5-1 −17,207 $28.85 $496,346 547,343 D: show line 2 in the form
Cloonan Michael President & CEO 2025-09-29 Option exercise 10b5-1 +7,793 $6.11 $47,615 555,136 D: show line 3 in the form
Cloonan Michael President & CEO 2025-09-29 Sale 10b5-1 −7,793 $29.70 $231,451 547,343 D: show line 4 in the form
Open-market sales · 25,000 sh · avg $29.11 · $727,798

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Cloonan Michael President & CEO 2025-09-26 Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 −17,207 185,935 D: show line 5 in the form
Cloonan Michael President & CEO 2025-09-29 Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 −7,793 178,142 D: show line 6 in the form
Loading xslF345X05/edgardoc.xml…